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O
n May 15, 2008, The American College of Cardiology/American Heart
Association/Heart Rhythm Society 2008 Guidelines for Device-Based Ther-
apy of Cardiac Rhythm Abnormalities were published online. Subsequently,
the guidelines were concurrently published in the Journal of the American College of
Cardiology, Circulation, and Heart Rhythm.1 The guidelines were developed in
collaboration with the American Association for Thoracic Surgery and the Society
of Thoracic Surgeons. Focusing on 3 areas—pacemakers for bradyarrhythmias and
heart failure management, cardiac resynchronization therapy (CRT), and implantable
cardioverter defibrillators (ICDs)—these guidelines update the previous version
published in 2002. The guidelines are comprehensive, and the reader is referred to
appropriate sections for recommendations related to specific clinical presentations.
This commentary will 1) provide a brief summary of several key recommendations,
highlighting notable changes in the guidelines and their relevance to surgical practice,
and 2) summarize the section on surgical considerations for device-based therapy.
Key Recommendations
Pacemakers
Indications for pacemaker therapy (eg, sinus node dysfunction and acquired atrioven-
tricular block) are well defined. The guidelines encourage optimization of pacemaker
programming to minimize unneeded right ventricular pacing. It is recognized that right
ventricular apical pacing may not be the best approach in many patients because this
mode of pacing has adverse effects on left ventricular (LV) and left atrial structure and
function and is associated with an increased incidence of atrial fibrillation and conges-
tive heart failure when compared with dual-chamber pacing. The role of biventricular
pacing in patients without heart failure is not yet well defined, although this may be
a reasonable option in selected young patients who require lifelong pacing. Pacemaker
implantation is discouraged for asymptomatic bradycardia, particularly when brady-
cardia occurs at night. Pacing is not indicated for prevention of atrial fibrillation.
Cardiac Resynchronization Therapy
The need for optimization of medical therapy before CRT implantation is emphasized.
CRT (with or without an ICD) is indicated (class IA recommendation) for patients
who are in New York Heart Association (NYHA) class III or ambulatory class IV
with optimal recommended medical therapy and who have a left ventricular ejection
fraction (LVEF) less than or equal to 35%, a QRS duration greater than or equal to
0.12 seconds, and sinus rhythm. Similar patients with atrial fibrillation may also
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CRT 5 cardiac resynchronization therapy
ICD 5 implantable cardioverter defibrillator
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
benefit from CRT. In patients meeting the aforementioned
criteria, CRT has been associated with improved LV systolic
function, favorable cardiac remodeling, and reduction in
functional mitral regurgitation, heart failure symptoms, hos-
pitalizations, and death. However, no large clinical trials have
demonstrated the benefits of CRT for patients without pro-
longation of the QRS interval (.0.12 seconds). CRT is not
indicated for asymptomatic patients with reduced LVEF in
the absence of other indications for pacing.
Implantable Cardioverter Defibrillators
ICDs are recommended in specific circumstances for pri-
mary and secondary prevention of sudden cardiac death;
secondary prevention refers to the prevention of sudden car-
diac death in patients who have survived a previous cardiac
arrest or sustained ventricular tachycardia. In such patients,
ICD therapy improves survival. ICD recommendations ap-
ply only to patients receiving optimal medical therapy
with a reasonable expectation of survival with good func-
tional capacity for more than 1 year. Of particular relevance
to surgeons, ICD therapy is indicated in the following
groups of patients:
 patients with an LVEF less than 35% because of a pre-
vious myocardial infarction who are at least 40 days
postmyocardial infarction and in NYHA class II or
III (class IA recommendation);
 patients with nonischemic dilated cardiomyopathy
who have an LVEF less than or equal to 35% and
who are in NYHA class II or III (class IB recommen-
dation); and
 patients with LV dysfunction because of previous
myocardial infarction who are at least 40 days post-
myocardial infarction, have an LVEF less than 30%,
and are in NYHA class I (class IA recommendation).
Surgical Considerations
The guidelines recognize that surgeons, with appropriate
training, may participate in device-based therapies of cardiac
rhythm abnormalities and heart failure. Surgeons may be in-
volved with the transvenous or epicardial placement of leads
and with the insertion of related generators and hardware.
Surgeons most frequently engage in the placement of epicar-
dial pacing leads.The Journal of ThoSurgically placed epicardial pacing leads are indicated in
selected instances when standard transvenous lead placement
is not feasible or contraindicated. Examples of such circum-
stances include 1) the inability or failure to place an adequate
LV lead in patients requiring biventricular pacing, 2) indica-
tions for permanent pacing in certain pediatric patients and in
pediatric or adult patients with tricuspid valve prostheses or
recurrent or prolonged bacteremia, and 3) congenital or
acquired venous anomalies that preclude transvenous access
to the heart.
Biventricular Pacing (Cardiac Resynchronization
Therapy)
The reported success rate of coronary venous lead implanta-
tion for CRT ranges from 81% to 99%. Causes of failed per-
cutaneous lead placement may be anatomic (superior vena
cava or coronary sinus obstruction or inadequate coronary
venous anatomy) or technical (failure to cannulate the coro-
nary sinus, coronary sinus dissection, inadequately high pac-
ing thresholds with intermittent capture, diaphragmatic
pacing because of proximity of the phrenic nerve to the target
coronary sinus branch, or lead dislodgement). When coro-
nary sinus lead implantation fails, several nonrandomized
studies have demonstrated that surgical LV lead placement
is almost always successful. The key advantage of surgical
lead placement is access to the entire posterior and lateral
walls of the left ventricle, which enables choice of the best
pacing site. The combination of echocardiography with tis-
sue Doppler imaging and electrophysiologic measurements
may facilitate the choice of a transthoracically directed LV
epicardial pacing site. Placement of 2 epicardial leads may
be considered to provide backup capability if one lead should
fail or become dislodged. Steroid-eluting epicardial leads are
generally preferable to screw-on leads.
The choice of surgical approach for LV epicardial leads
seems to influence hospital morbidity. Surgical approaches
for the placement of LV epicardial leads include left thora-
cotomy, left thoracoscopy, and robotically assisted port-
based placement. Thoracotomy in frail patients with heart
failure has been associated with bleeding, stroke, hypoten-
sion, and arrhythmias. In contrast, thoracoscopic and robotic
approaches have been reported to be associated with minimal
morbidity and are preferred. These less-invasive procedures
generally require 60 to 90 minutes of operative time and
a mean hospital stay of 4 to 5 days. However, not all patients
are candidates for minimally invasive or robotic procedures.
Patients who have undergone a previous thoracotomy or ster-
notomy may have limited pericardial/epicardial access.
In certain instances, it may be advisable to place an LV
epicardial lead at the time of concomitant cardiac surgery.
In patients who are currently or in the future may be
candidates for CRT who require coronary artery bypass
grafting or mitral valve surgery and who have medically re-
fractory, symptomatic heart failure, ischemic or dilatedracic and Cardiovascular Surgery c Volume 136, Number 2 281
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diameter greater than or equal to 55 mm, and ejection frac-
tion less than or equal to 35%, the surgeon may elect to place
an LV epicardial lead. The lead is tunneled to a prepectoral
pocket for intraoperative or postoperative attachment to an
appropriate pacing generator. This approach is probably
not indicated for the patient who is expected to have substan-
tial improvement in LVEF after cardiac surgery (eg, a patient
with extensive viable myocardium undergoing revasculari-
zation). There are limited data documenting outcomes of
this ‘‘preemptive’’ strategy.
Pediatric Patients
Epicardial leads may be necessary in some pediatric patients.
The most common indications for permanent pacemaker
implantation in the pediatric population are sinus node dys-
function or atrioventricular block after surgery for congenital
heart disease or congenital atrioventricular block. In most
instances, such pacing systems can be placed using standard
transvenous techniques. However, epicardial leads may be
needed in children as a result of their small size, the presence
of congenital heart defects with a right-to-left shunt, or an
inability to pace the chamber desired because of anatomic
barriers (eg, after a Fontan procedure). In such instances,
steroid-eluting leads provide excellent durability.
Bacteremia
Epicardial leads are suggested in some pediatric or adult pa-
tients who need pacing and who have recurrent or prolonged
bacteremia. For a single episode of device-related bacter-
emia, extraction of all hardware followed by reimplantation
by the transvenous route at a later date is appropriate.282 The Journal of Thoracic and Cardiovascular Surgery c AugTricuspid Valve Surgery
Implantation of permanent epicardial pacing leads is indi-
cated in the pacemaker-dependent patient undergoing tricus-
pid valve replacement. A mechanical tricuspid valve
represents an absolute contraindication to placement of trans-
venous right ventricular leads, because such leads will cross
the valve and interfere with valve function. This scenario oc-
curs most commonly in the patient with tricuspid valve endo-
carditis and a transvenous pacemaker. At surgery, all
hardware should be removed. If the tricuspid valve is repara-
ble, standard transvenous pacing leads can be placed postop-
eratively. However, if tricuspid valve replacement is
necessary, epicardial ventricular leads should be implanted
at the time of surgery.
Conclusions
With appropriate training, surgeons can place both endovas-
cular and epicardial leads and corresponding generators. The
newly issued American College of Cardiology/American
Heart Association/Heart Rhythm Society 2008 Guidelines
for Device-Based Therapy of Cardiac Rhythm Abnormali-
ties1 provide detailed, well-referenced recommendations to
guide patient selection and device type.
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